EGF Theramed Health (TMED.X) AI Stock Analysis

EGF Theramed Health

(CNQX:TMED.X)

Select Model

Rating:38Underperform

Price Target:CAD 0.08▲(87.50% Upside)

Action:reiterated

Date:12/30/25

The score is driven down primarily by very weak financial performance (no revenue, ongoing losses, negative equity and a thin asset base), compounded by strongly bearish technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation offers limited support because earnings are negative and no dividend yield is available.

Positive Factors

Improving Cash GenerationThe shift to slightly positive operating and free cash flow in 2025 signals emerging cash generation after several years of negative flows. Although the amount is small, sustained positive cash flow would reduce near-term financing needs and provide a foundation for incremental investment or product commercialization.

Negative Factors

No Reported RevenueZero reported revenue across the available periods shows the company lacks commercialized products or monetization. Without recurring revenue, long-term viability depends on successful product launches or continual external funding, substantially increasing execution and dilution risk for stakeholders.

EGF Theramed Health (TMED.X) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 813.17K
Dividend Yield: ―
Average Volume (3M): 1,000
Price to Earnings (P/E): -0.4
Beta (1Y): 0.10
Revenue Growth: ―
EPS Growth: 69.09%
Country: Canada
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

EGF Theramed Health Business Overview & Revenue Model

Company Description

EGF Theramed Health Corp. focuses on providing psychedelic-based therapies to address various mental health challenges. The company's products are specifically utilized in the treatment of conditions such as intractable depression, anxiety disorders,...

How the Company Makes Money

null

EGF Theramed Health Financial Statement Overview

Summary

Financial quality is very weak: revenue is reported at $0 across all years, losses persist and worsened in 2025, and operating results (EBIT/EBITDA) remain negative. The balance sheet is highly stressed with negative equity (2022–2025), a very small asset base, and meaningful debt—indicating elevated solvency and dilution risk. Cash flow improved with slightly positive operating/free cash flow in 2025, but the magnitude is small and volatility remains high.

Income Statement

6Very Negative

Balance Sheet

4Very Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	―
EBITDA	-2.21M	-2.33M	-238.64K	-568.50K	-1.35M	-677.89K
Net Income	-3.09M	-3.21M	-269.25K	-623.00K	-1.69M	-968.71K
Balance Sheet
Total Assets	18.25K	22.34K	214.41K	193.69K	178.67K	1.20M
Cash, Cash Equivalents and Short-Term Investments	10.47K	14.01K	10.01K	11.72K	15.23K	702.63K
Total Debt	1.63M	1.51M	1.47M	1.34M	1.22M	1.12M
Total Liabilities	6.06M	5.93M	2.92M	2.67M	2.51M	2.41M
Stockholders Equity	-4.64M	-4.52M	-1.34M	-1.14M	-1.02M	91.48K
Cash Flow
Free Cash Flow	82.28K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Operating Cash Flow	82.30K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Investing Cash Flow	0	0	0	0	0	410.43K
Financing Cash Flow	104.98K	-25.75K	133.00K	572.50K	306.02K	712.20K

EGF Theramed Health Technical Analysis

Technical Analysis SentimentNegative

Last Price0.04

Price Trends

50DMA0.06Negative

100DMA0.06Negative

200DMA0.07Negative

Market Momentum

MACD-0.00Positive

RSI0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED.X, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 0.00 is Positive, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TMED.X.

EGF Theramed Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:TMED.X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:NDAT	45Neutral	CAD 2.89M	-16.67	-49.83%	―	―	0.00%
TSE:DMED	39Underperform	CAD 3.95M	-1.94	739.84%	―	―	-28.35%
TSE:KETA	38Underperform	CAD 3.31M	-19.19	5.31%	―	―	―
TSE:NARA	38Underperform	CAD 2.39M	-0.82	184.91%	―	―	43.30%
TSE:TMED.X	38Underperform	CAD 464.67K	-0.38	66.83%	―	―	69.09%

* Healthcare Sector Average

Performance Comparison

TSE:TMED.X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:TMED.X	Egf Theramed Health Corp.	0.04	-0.08	-65.22%
TSE:NDAT	nDatalyze Corp	0.07	0.06	366.67%
TSE:KETA	TripSitter Clinic Ltd	0.19	0.14	245.45%
TSE:NARA	PanGenomic Health, Inc. Class A	0.17	-1.03	-85.83%
TSE:DMED	DiagnaMed Holdings Corp.	0.03	-0.06	-64.71%

EGF Theramed Health Corporate Events

Business Operations and StrategyExecutive/Board Changes

EGF Theramed refreshes board and finance leadership

Positive

Mar 4, 2026

EGF Theramed Health Corp. has appointed Lin Ye to its board of directors and named Connor Yuen as interim chief financial officer, following the resignation of former CFO and director Usama Chaudhry. The changes bring leadership with experience in ga...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 30, 2025

EGF Theramed Health AI Stock Analysis